InsiderTrades.com logo

NRSN Insider Trading

Insider Ownership Percentage: 27.40%
Insider Buying (Last 12 Months): $400,000.00
Insider Selling (Last 12 Months): $0.00

NeuroSense Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at NeuroSense Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

NeuroSense Therapeutics Share Price & Price History

Current Price: $0.71
Price Change: ▲ Price Increase of +0.006 (0.86%)
As of 06/17/2026 04:00 PM ET

This chart shows the closing price history over time for NRSN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

NeuroSense Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/16/2026Alon Ben-NoonCEOBuy250,000$0.80$200,000.004,534,233View SEC Filing Icon  
6/16/2026Or EisenbergCFOBuy250,000$0.80$200,000.001,504,050View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for NeuroSense Therapeutics (NASDAQ:NRSN)

1.04% of NeuroSense Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at NRSN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

NeuroSense Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/13/2026Yorkville Advisors Global LP78,000$59K0.0%-22.0%0.240%Search for SEC Filing on Google Icon
2/10/2026Yorkville Advisors Global LP100,000$77K0.0%N/A0.732%Search for SEC Filing on Google Icon
11/14/2025Two Sigma Investments LP21,086$26K0.0%N/A0.154%Search for SEC Filing on Google Icon
11/14/2025Squarepoint Ops LLC95,375$0.12M0.0%+91.0%0.698%Search for SEC Filing on Google Icon
8/14/2025Jane Street Group LLC28,689$54K0.0%N/A0.210%Search for SEC Filing on Google Icon
2/17/2025Citadel Advisors LLC253,997$0.31M0.0%+640.9%1.858%Search for SEC Filing on Google Icon
2/14/2025Jane Street Group LLC64,636$78K0.0%N/A0.473%Search for SEC Filing on Google Icon
11/15/2024XTX Topco Ltd45,996$58K0.0%+40.9%0.336%Search for SEC Filing on Google Icon
8/15/2024Armistice Capital LLC1,584,000$1.77M0.0%N/A11.591%Search for SEC Filing on Google Icon
8/12/2024XTX Topco Ltd32,650$37K0.0%N/A0.239%Search for SEC Filing on Google Icon
11/15/2023Armistice Capital LLC662,000$0.47M0.0%-47.7%6.051%Search for SEC Filing on Google Icon
5/11/2023Meitav Investment House Ltd.95,000$0.19M0.0%N/A0.868%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
NeuroSense Therapeutics logo
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Read More on NeuroSense Therapeutics

Today's Range

Now: $0.71
Low: $0.69
High: $0.74

50 Day Range

MA: $0.78
Low: $0.69
High: $0.95

52 Week Range

Now: $0.71
Low: $0.63
High: $2.52

Volume

281,996 shs

Average Volume

176,305 shs

Market Capitalization

$22.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56

Who are the company insiders with the largest holdings of NeuroSense Therapeutics?

NeuroSense Therapeutics' top insider shareholders include:
  1. Alon Ben-Noon (CEO)
  2. Or Eisenberg (CFO)
Learn More about top insider investors at NeuroSense Therapeutics.

Who are the major institutional investors of NeuroSense Therapeutics?

NeuroSense Therapeutics' top institutional investors include:
  1. Yorkville Advisors Global LP — 0.24%
Learn More about top institutional investors of NeuroSense Therapeutics stock.

Which institutional investors are selling NeuroSense Therapeutics stock?

In the last quarter, NRSN stock was sold by these institutional investors:
  1. Yorkville Advisors Global LP